Effectlessness of a new spasmolytic (rociverine) on intraocular pressure, pupil size, and iridocorneal angle in ophthalmically healthy subjects.
Thirty-seven subjects without eye diseases were treated with rociverine, a new direct myolytic and parasympatholytic antispasmodic: 15 by intravenous injection (20 mg) and 22 by oral administration (20 mg three times daily for four days). Intraocular pressure, pupil size, iridocorneal angle, blood pressure, and heart rate were checked before and during treatment. No clinically significant variations were observed in the parameters tested.
D000328:Adult; D001643:Bridged Bicyclo Compounds / Q000009:adverse effects*; D001952:Bridged-Ring Compounds / Q000009:adverse effects*; D003315:Cornea / Q000187:drug effects; D003509:Cyclohexanecarboxylic Acids; D005123:Eye / Q000187:drug effects*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007498:Iris / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects*; D011680:Pupil / Q000187:drug effects
D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D003509:Cyclohexanecarboxylic Acids; D010276:Parasympatholytics; C021082:rociverine